Daniel L Abravanel

7PUBLICATIONS
74CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Nov 29, 2025
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer.

Jingxin Fu, Adrienne G Waks, Erica Pimenta

|Nov 28, 2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.

Adrienne G Waks, Jingxin Fu, Xiangying Chu

|Mar 29, 2025
Author Correction: A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.

Johanna Klughammer, Daniel L Abravanel, Åsa Segerstolpe

|Oct 31, 2024
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.

Johanna Klughammer, Daniel L Abravanel, Åsa Segerstolpe

|Mar 20, 2024
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.

Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain

Pageof 2

Frequent Collaborators

6 joint publications

Sara M Tolaney

5 joint publications

Nikhil Wagle

3 joint publications

Edward S Boyden

3 joint publications

Ann Partridge